1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
"1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
| Descriptor ID |
D019307
|
| MeSH Number(s) |
D02.886.590.700.545 D03.383.606.527 D03.633.100.531.400
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine".
Below are MeSH descriptors whose meaning is more specific than "1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine".
This graph shows the total number of publications written about "1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine" by people in this website by year, and whether "1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine" by people in Profiles.
-
A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy. Cornea. 2021 Oct 01; 40(10):1225-1228.
-
Novel Murine Models of Cerebral Cavernous Malformations. Angiogenesis. 2020 11; 23(4):651-666.
-
Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease. Stroke. 2019 03; 50(3):738-744.
-
RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. Stroke. 2017 01; 48(1):187-194.
-
Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension. Hypertens Res. 2015 Aug; 38(8):539-44.
-
Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations. Genet Med. 2015 Mar; 17(3):188-196.
-
Inhibition of Rho-kinase attenuates endothelial-leukocyte interaction during ischemia-reperfusion injury. Vasc Med. 2012 Dec; 17(6):379-85.
-
Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease. Stroke. 2012 Feb; 43(2):571-4.
-
Rho-associated kinase activity, endothelial function, and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2011 Oct; 31(10):2353-9.
-
Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil. Atherosclerosis. 2011 Jan; 214(1):117-21.